The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites

被引:4
|
作者
Kim, Jun Jae [1 ]
Kim, Jeong Han [1 ]
Koo, Ja Kyung [1 ]
Choi, Yun Jung [1 ]
Ko, Soon Young [1 ]
Choe, Won Hyeok [1 ]
Kwon, So Young [1 ]
机构
[1] Konkuk Univ, Sch Med, Digest Dis Ctr, Dept Internal Med, Seoul, South Korea
关键词
End Stage Liver Disease; Liver Cirrhosis; Ascites; Mortality; Hyponatremia;
D O I
10.3350/cmh.2014.20.1.47
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The modification of the Model for End-Stage Liver Disease (MELD) scoring system (Refit MELD) and the modification of MELD-Na (Refit MELDNa), which optimized the MELD coefficients, were published in 2011. We aimed to validate the superiority of the Refit MELDNa over the Refit MELD for the prediction of 3-month mortality in Korean patients with cirrhosis and ascites. Methods: We reviewed the medical records of patients admitted with hepatic cirrhosis and ascites to the Konkuk University Hospital between January 2006 and December 2011. The Refit MELD and Refit MELDNa were compared using the predictive value of the 3-month mortality, as assessed by the Child-Pugh score. Results: In total, 530 patients were enrolled, 87 of whom died within 3 months. Alcohol was the most common etiology of their cirrhosis (n= 271, 51.1%), and the most common cause of death was variceal bleeding (n= 20, 23%). The areas under the receiver operating curve (AUROCs) for the Child-Pugh, Refit MELD, and Refit MELDNa scores were 0.754, 0.791, and 0.764 respectively; the corresponding values when the analysis was performed only in patients with persistent ascites (n= 115) were 0.725, 0.804, and 0.796, respectively. The significant difference found among the Child-Pugh, Refit MELD, and Refit MELDNa scores was between the Child-Pugh score and Refit MELD in patients with persistent ascites (P= 0.039). Conclusions: Refit MELD and Refit MELDNa exhibited good predictability for 3-month mortality in patients with cirrhosis and ascites. However, Refit MELDNa was not found to be a better predictor than Refit MELD, despite the known relationship between hyponatremia and mortality in cirrhotic patients with ascites.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 50 条
  • [41] Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis
    Zmora, Niv
    Bannon, Lian
    Shibolet, Oren
    Rabinowich, Liane
    JOURNAL OF HEPATOLOGY, 2023, 78 : S243 - S244
  • [42] Model for end-stage liver disease-Na score or Maddrey discrimination function index, which score is best?
    Amieva-Balmori, Mercedes
    Isabel Mejia-Loza, Scherezada Maria
    Ramos-Gonzalez, Roberto
    Zamarripa-Dorsey, Felipe
    Garcia-Ruiz, Eli
    Perez y Lopez, Nuria
    Juarez-Valdes, Eumir, I
    Lopez-Luria, Adriana
    Maria Remes-Troche, Jose
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (17) : 2119 - 2126
  • [43] The pediatric end-stage liver disease (PELD) model as a predictor of post-transplant mortality
    Barshes, NR
    Karpen, SJ
    Carter, BA
    O'Mahony, CA
    Goss, JA
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 527 - 527
  • [44] Multivariate analyses for hepatic cirrhosis and evaluation of the model for end-stage liver disease
    Wen, Zhuofu
    Lin, Jing-Hua
    Zheng, Fengping
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A216 - A216
  • [45] Cirrhosis Prognostic Quantification with Ultrasound: An Approximation to Model for End-Stage Liver Disease
    Ribeiro, Ricardo
    Marinho, Rui Tato
    Sanches, Joao Miguel
    PATTERN RECOGNITION AND IMAGE ANALYSIS, IBPRIA 2013, 2013, 7887 : 551 - 558
  • [46] Preoperative model for end-stage liver disease score as a predictor for posthemihepatectomy complications
    Alghamdi, Thamer
    Abdel-Fattah, Muataz
    Zautner, Andreas
    Lorf, Thomas
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (06) : 668 - 675
  • [47] Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver Cirrhosis
    Yoo, Seung-Kang
    Kim, Jeong-Han
    Choe, Won-Hyeok
    Kwon, So-Young
    MEDICINA-LITHUANIA, 2025, 61 (03):
  • [48] Model for end-stage liver disease (MELD) exception for polycystic liver disease
    Arrazola, Luis
    Moonka, Dilip
    Gish, Robert G.
    Everson, Gregory T.
    LIVER TRANSPLANTATION, 2006, 12 (12) : S110 - S111
  • [49] Impact of the Model for End-Stage Liver Disease Score on Mortality After Liver Transplantation
    Cabeza de Vaca, V. G.
    Bellido, C. B.
    Martinez, J. N. A.
    Artacho, G. S.
    Gomez, L. M. M.
    Diaz-Canedo, J. S.
    Ruiz, F. J. P.
    Bravo, M. A. G.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (07) : 2069 - 2070